$ESRX Express Scripts (ESRX) Overall Average: 48% Buy. Tuesday,

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
$ESRX Overall Average: 48% Buy. $ARNA $BBBY $FTR

Express Scripts (ESRX) Buy - Hold - Sell - Overall Opinion

ESRX Last Price: 76.69
Current Change: -0.67 (-0.87%)

Composite Indicators - Signal
TrendSpotter- Buy

Short Term Indicators
7 Day Average Directional Indicator - Sell
10 - 8 Day Moving Average Hilo Channel - Sell
20 Day Moving Average vs Price- Buy
20 - 50 Day MACD Oscillator- Buy
20 Day Bollinger Bands® - Hold

Short Term Indicators Average: 0% Hold
20-Day Average Volume - 6,209,825



Medium Term Indicators
40 Day Commodity Channel Index - Hold
50 Day Moving Average vs Price- Buy
20 - 100 Day MACD Oscillator- Buy
50 Day Parabolic Time/Price- Buy

Medium Term Indicators Average: 75% Buy
50-Day Average Volume - 5,260,940

Long Term Indicators
60 Day Commodity Channel Index - Hold
100 Day Moving Average vs Price- Buy
50 - 100 Day MACD Oscillator- Buy

Long Term Indicators Average: 67% Buy
100-Day Average Volume - 5,026,151

Overall Average: 48% Buy

Price - Support - Pivot Point - Resistance
76.69 75.84 77.00 78.16


Last Updated: Tuesday, March 18, 2014 07:35:02 AM

ESRX Stock Message Board and Forum http://investorshangout.com/search?q=ESRX&...mp;yt0=Go!
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Valour Inc. Unveils Advanced Leveraged ETPs for Crypto Trading

Updated Category News Views 86

Valour Inc. Launches Innovative Leveraged ETPs Valour Inc., a subsidiary of DeFi Technologies, is making waves in the financial technology sector by launching leveraged exchange-traded products (ETPs) focused on Bitcoin and Ethereum. These new offerings, titled Bull Bitcoin X2 Valour and Bull Ethereum X2 Valour, deliver twice the daily exposure to these leading...

Continue Reading
Inhibikase Therapeutics Makes Headway with $275 Million Financing

Updated Category News Views 84

Introduction to Inhibikase Therapeutics Inhibikase Therapeutics, Inc. (NASDAQ: IKT) is a pioneering clinical-stage pharmaceutical company dedicated to creating innovative therapeutics for cardiopulmonary and neurodegenerative diseases. Their commitment to developing high-quality treatments is evident in the recent announcement regarding an impressive financing deal....

Continue Reading
JBS USA Food Company's Successful Tender Offer for Notes

Updated Category News Views 341

Overview of the Tender Offer by JBS USA Food Company JBS USA Food Company recently shared exciting news about the successful conclusion of its cash tender offer for its 2.500% Senior Notes due 2027. The offer was designed for any and all outstanding notes, aimed at strengthening the company's financial position. Details on Tender Offer Results As reported, the results...

Continue Reading
Imaflex's Impressive Q2 2025 Results Show Resilience

Updated Category News Views 114

Strong Balance Sheet and Operational Agility Support Future Growth In a world where market dynamics can shift unexpectedly, Imaflex Inc. is finding ways to maintain robust performance despite the prevailing challenges. The company recently released its financial results for the second quarter of 2025 with notable highlights that showcase its resilience and strategic...

Continue Reading
A Decade of Growth: The Journey of Penumbra Stock Value

Updated Category News Views 158

Understanding Penumbra's Growth Over the Last Decade Penumbra (NYSE: PEN) has shown remarkable growth over the past decade, achieving an annualized return of 20.49%. This performance eclipses the market by an impressive 7.83% annually, making it a notable player in the healthcare sector. The Impact of Compounding Returns When it comes to investing, one fundamental...

Continue Reading